Variable name;level;Overall;Grade I-II;Grade III;p;test
;n;1357;586;760;;
Age;[0 -40);801 (59.1);306 (52.2);487 (64.2);<0.001;
;40+;554 (40.9);280 (47.8);272 (35.8);;
Age (mean);;38.7 [34.9, 41.6];39.7 [35.6, 42.1];38.0 [34.2, 41.1];<0.001;nonnorm
Number of children;0;373 (27.5);145 (24.7);224 (29.5);0.002;
;1;279 (20.6);105 (17.9);174 (22.9);;
;More than 1;705 (52.0);336 (57.3);362 (47.6);;
BMI;<18.5;79 (6.3);30 (5.6);49 (7.0);0.553;
;25-29.9;257 (20.6);106 (19.7);149 (21.2);;
;>=30;107 (8.6);50 (9.3);55 (7.8);;
;18.5-24.9;807 (64.6);351 (65.4);451 (64.1);;
BMI (mean);;22.6 [20.5, 25.5];22.8 [20.4, 25.4];22.5 [20.5, 25.6];0.659;nonnorm
Treatment center;Curie Paris;818 (60.3);329 (56.1);483 (63.6);NaN;
;Curie St Cloud;538 (39.7);257 (43.9);277 (36.4);;
;Others;0 (0.0);0 (0.0);0 (0.0);;
Genetic Analysis;No;656 (48.3);338 (57.7);313 (41.2);<0.001;
;Yes;701 (51.7);248 (42.3);447 (58.8);;
Hereditary predisposition;No;547 (79.6);202 (84.5);339 (76.7);0.021;
;Yes;140 (20.4);37 (15.5);103 (23.3);;
Inflammatory BC;No;1338 (98.7);579 (98.8);749 (98.6);0.872;
;Yes;18 (1.3);7 (1.2);11 (1.4);;
Clinical Tumor size (mm);;30.3 (21.7);28.9 (21.2);31.4 (22.0);0.038;
Clinical N stage (TNM);N0;854 (63.4);376 (64.7);471 (62.3);0.395;
;N1-N2-N3;492 (36.6);205 (35.3);285 (37.7);;
Histological type;NST;1265 (93.4);530 (90.4);729 (95.9);<0.001;
;Lobular;54 (4.0);45 (7.7);9 (1.2);;
;Others;36 (2.7);11 (1.9);22 (2.9);;
Neoajuvant chemotherapy;No;744 (54.9);378 (64.5);358 (47.1);<0.001;
;Yes;612 (45.1);208 (35.5);402 (52.9);;
Chemotherapy setting;NAC;611 (45.1);208 (35.5);401 (52.8);NaN;
;Adjuvant;744 (54.9);378 (64.5);358 (47.1);;
;NAC and adjuvant;0 (0.0);0 (0.0);0 (0.0);;
;Chemotherapy without surgery;1 (0.1);0 (0.0);1 (0.1);;
;No;0 (0.0);0 (0.0);0 (0.0);;
Fertility preservation discussion;No;909 (67.0);420 (71.7);482 (63.4);0.002;
;Yes;447 (33.0);166 (28.3);278 (36.6);;
